Skip to main navigation
Supernus Pharmaceuticals

Header Links

  • Return to Supernus.com

Investor Relations

  • Overview
  • News & Events
    Press Releases Events & Presentations
  • Governance
    Corporate Governance Management Board of Directors Committee Composition Contact the Board
  • Financials & Filings
    Financials & Filings SEC Filings Annuals & Proxies Quarterly Results
  • Stock
    Stock Information Historic Stock Lookup Investment Calculator Ownership Profile
  • Contact Us

Investor Relations

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Governance
    • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials & Filings
    • Financials & Filings
    • SEC Filings
    • Annuals & Proxies
    • Quarterly Results
  • Stock
    • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Ownership Profile
  • Contact Us

    Breadcrumb

  1. Investor Relations
  2. taxonomy
  3. term
  4. General Releases

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

  • Read more about Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

  • Read more about Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

  • Read more about Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

  • Read more about Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

  • Read more about Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

  • Read more about Supernus Announces Paragraph IV ANDA Filings for Qelbree®

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

  • Read more about Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

  • Read more about Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

Supernus Announces First Quarter 2025 Financial Results

  • Read more about Supernus Announces First Quarter 2025 Financial Results

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

  • Read more about Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to General Releases

Shareholder Tools


Email Alerts


RSS Feeds


Search

Back to Top
Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
Rockville, MD 20850
(301) 838-2500
info@supernus.com

Back to Top

© 2026 Supernus Pharmaceuticals

Post Footer Links

  • Sitemap
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • State Policy
  • Social Media Community Guidelines